The relationship between carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer

Mitsuru Miyazaki, Yasuhiro Fujiwara, Takeshi Isobe, Michio Yamakido, Takashi Kato, Hiroshi Miyazaki

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

To clarify the relationship between the carboplatin AUC and the extent of damage to thrombopoiesis, we monitored both endogenous serum TPO kinetics and carboplatin pharmacokinetics after single-agent carboplatin administration. Previously untreated 12 patients with stage IV non-small-cell lung cancer were enrolled. The actual carboplatin AUC showed a significant positive correlation with the maximum increase ratio of TPO (TPO(max)/TPO(day1) (r = 0.74, p = 0.014). Furthermore, the increase ratio of TPO at one week after administration of carboplatin (TPO(day8)/TPO(day1) showed a significant negative correlation with the following platelet nadir around day 19 (r = -0.84, p = 0.005). By monitoring the changes in endogenous TPO concentration, we could estimate the degree of thrombocytopenia and determine the indication, and thus the optimal timing of prophylactic administration of TPO before platelets are markedly reduced.

Original languageEnglish
Pages (from-to)667-670
Number of pages4
JournalAnticancer Research
Volume19
Issue number1 B
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Thrombopoietin
Carboplatin
Area Under Curve
Lung Neoplasms
Serum
Blood Platelets
Thrombopoiesis
Non-Small Cell Lung Carcinoma
Thrombocytopenia
Pharmacokinetics

Keywords

  • Carboplatin
  • Lung cancer
  • Pharmacokinetics
  • Thrombocytopenia
  • Thrombproietin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Miyazaki, M., Fujiwara, Y., Isobe, T., Yamakido, M., Kato, T., & Miyazaki, H. (1999). The relationship between carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer. Anticancer Research, 19(1 B), 667-670.

The relationship between carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer. / Miyazaki, Mitsuru; Fujiwara, Yasuhiro; Isobe, Takeshi; Yamakido, Michio; Kato, Takashi; Miyazaki, Hiroshi.

In: Anticancer Research, Vol. 19, No. 1 B, 1999, p. 667-670.

Research output: Contribution to journalArticle

Miyazaki, M, Fujiwara, Y, Isobe, T, Yamakido, M, Kato, T & Miyazaki, H 1999, 'The relationship between carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer', Anticancer Research, vol. 19, no. 1 B, pp. 667-670.
Miyazaki, Mitsuru ; Fujiwara, Yasuhiro ; Isobe, Takeshi ; Yamakido, Michio ; Kato, Takashi ; Miyazaki, Hiroshi. / The relationship between carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer. In: Anticancer Research. 1999 ; Vol. 19, No. 1 B. pp. 667-670.
@article{d3b2ff7dbed04df1bd0762c4905ab150,
title = "The relationship between carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer",
abstract = "To clarify the relationship between the carboplatin AUC and the extent of damage to thrombopoiesis, we monitored both endogenous serum TPO kinetics and carboplatin pharmacokinetics after single-agent carboplatin administration. Previously untreated 12 patients with stage IV non-small-cell lung cancer were enrolled. The actual carboplatin AUC showed a significant positive correlation with the maximum increase ratio of TPO (TPO(max)/TPO(day1) (r = 0.74, p = 0.014). Furthermore, the increase ratio of TPO at one week after administration of carboplatin (TPO(day8)/TPO(day1) showed a significant negative correlation with the following platelet nadir around day 19 (r = -0.84, p = 0.005). By monitoring the changes in endogenous TPO concentration, we could estimate the degree of thrombocytopenia and determine the indication, and thus the optimal timing of prophylactic administration of TPO before platelets are markedly reduced.",
keywords = "Carboplatin, Lung cancer, Pharmacokinetics, Thrombocytopenia, Thrombproietin",
author = "Mitsuru Miyazaki and Yasuhiro Fujiwara and Takeshi Isobe and Michio Yamakido and Takashi Kato and Hiroshi Miyazaki",
year = "1999",
language = "English",
volume = "19",
pages = "667--670",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 B",

}

TY - JOUR

T1 - The relationship between carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer

AU - Miyazaki, Mitsuru

AU - Fujiwara, Yasuhiro

AU - Isobe, Takeshi

AU - Yamakido, Michio

AU - Kato, Takashi

AU - Miyazaki, Hiroshi

PY - 1999

Y1 - 1999

N2 - To clarify the relationship between the carboplatin AUC and the extent of damage to thrombopoiesis, we monitored both endogenous serum TPO kinetics and carboplatin pharmacokinetics after single-agent carboplatin administration. Previously untreated 12 patients with stage IV non-small-cell lung cancer were enrolled. The actual carboplatin AUC showed a significant positive correlation with the maximum increase ratio of TPO (TPO(max)/TPO(day1) (r = 0.74, p = 0.014). Furthermore, the increase ratio of TPO at one week after administration of carboplatin (TPO(day8)/TPO(day1) showed a significant negative correlation with the following platelet nadir around day 19 (r = -0.84, p = 0.005). By monitoring the changes in endogenous TPO concentration, we could estimate the degree of thrombocytopenia and determine the indication, and thus the optimal timing of prophylactic administration of TPO before platelets are markedly reduced.

AB - To clarify the relationship between the carboplatin AUC and the extent of damage to thrombopoiesis, we monitored both endogenous serum TPO kinetics and carboplatin pharmacokinetics after single-agent carboplatin administration. Previously untreated 12 patients with stage IV non-small-cell lung cancer were enrolled. The actual carboplatin AUC showed a significant positive correlation with the maximum increase ratio of TPO (TPO(max)/TPO(day1) (r = 0.74, p = 0.014). Furthermore, the increase ratio of TPO at one week after administration of carboplatin (TPO(day8)/TPO(day1) showed a significant negative correlation with the following platelet nadir around day 19 (r = -0.84, p = 0.005). By monitoring the changes in endogenous TPO concentration, we could estimate the degree of thrombocytopenia and determine the indication, and thus the optimal timing of prophylactic administration of TPO before platelets are markedly reduced.

KW - Carboplatin

KW - Lung cancer

KW - Pharmacokinetics

KW - Thrombocytopenia

KW - Thrombproietin

UR - http://www.scopus.com/inward/record.url?scp=0032945856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032945856&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 667

EP - 670

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 B

ER -